ArticlePloS one2026
Development of a cAMP biosensor-based assay for measuring serum bioactive concentrations of FSH.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicle-stimulating hormone (FSH) plays a pivotal role in reproductive physiology and is increasingly recognized for its involvement in the extragonadal system. The biological activity of FSH, which is modulated by glycosylation, varies with age, reproductive status, and pathological conditions. Although the serum FSH immunoreactive concentrations are measured routinely for patients with reproductive disorders, the significance of assessing the biological activity of FSH remains unclear. In this study, we aimed to develop a novel, rapid, and animal-free assay to quantify FSH bioactive concentrations using HEK293 cells co-expressing the human FSH receptor (FSHR) and a cyclic adenosine monophosphate biosensor. The assay demonstrated high specificity, reproducibility, and linearity, with minimal cross-reactivity with structurally related hormones. Application to clinical serum samples from postmenopausal women revealed a strong correlation between FSH immunoreactive and bioactive concentrations. Notably, estrogen replacement therapy resulted in a significant reduction in both FSH immunoreactive and bioactive concentrations, as well as in the FSH bioactive -to-immunoreactive concentration ratio, suggesting that FSH glycosylation patterns may have been altered, leading to a decrease in its bioactive concentrations. The findings collectively suggested that assessing FSH bioactive concentrations, in addition to immunoreactive concentrations, may provide further insights into hormonal regulation and its relevance to therapeutic evaluation. The biosensor-based assay could offer a practical and efficient tool for advancing our understanding of FSH function in both reproductive and non-reproductive contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.